ACP
CRBU icon

Arcus Capital Partners’s Caribou Biosciences CRBU Stock Holding History

Arcus Capital Partners’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,200
Closed -$20.1K – 165
2022
Q4 		$20.1K Buy
+3,200
New +$28.5K 0.01% 228

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arcus Capital Partners's CRBU Position: Q1 2023 in Review

Arcus Capital Partners sold out of Caribou Biosciences (CRBU) in Q1 2023, closing a stake of 3,200 shares — an estimated $20.1K sold.

Arcus Capital Partners first reported a position in CRBU in Q4 2022 and held it in 1 quarter. The position peaked at $20.1K in Q4 2022. 126 funds tracked by Wall St. Rank hold CRBU as of Q1 2023.

  • Arcus Capital Partners reported no remaining Caribou Biosciences position as of Q1 2023 after selling out during the quarter.
  • Arcus Capital Partners sold 3,200 Caribou Biosciences shares in Q1 2023, an estimated $20.1K.
  • Arcus Capital Partners first reported a position in Caribou Biosciences in Q4 2022 and held it in 1 quarter.
  • Arcus Capital Partners's Caribou Biosciences position peaked at $20.1K in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2023.

Based on Arcus Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.